Related Experiment Video
Updated: Nov 27, 2025

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
M Cynthia Martin1, Guihua Zeng2, Jindan Yu2,3,4
1Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, United States.
Polycomb Repressive Complex 2 (PRC2) is crucial for gene silencing and cell differentiation. New small molecules targeting PRC2 are being developed as potential anticancer therapeutics by inhibiting its function or disrupting its complex formation.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- Polycomb Repressive Complex 2 (PRC2) is a key epigenetic regulator.
- It catalyzes histone H3 lysine 27 (H3K27) methylation, mediating gene silencing.
- PRC2 is vital for stem cell identity and cellular differentiation.
Purpose of the Study:
- To review recent strategies for developing small molecules targeting PRC2.
- To explore therapeutic potential of targeting PRC2 in cancer.
Main Methods:
- Inhibition of individual PRC2 core proteins (EZH2, EED, SUZ12).
- Disruption of PRC2 complex formation.
- Targeted degradation of PRC2 subunits.
Main Results:
- Overexpression/mutation of PRC2 is frequent in cancers like prostate cancer and lymphoma.
- Aberrant PRC2 function contributes to uncontrolled proliferation and tumorigenesis.
- Development of small molecules targeting PRC2 is a promising therapeutic avenue.
Conclusions:
- Targeting PRC2 offers a novel strategy for cancer therapy.
- Diverse approaches are being investigated to inhibit PRC2 activity.
- Small molecules targeting PRC2 hold potential for anticancer drug development.
More Related Videos
10:05Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin
Published on: January 20, 2016
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Inhibition of Cdk Activity
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Epigenetic Regulation
X-chromosome...